These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39386453)

  • 1. Assessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer's disease: a multi-tracer PET study.
    Salardini E; O'Dell RS; Tchorz E; Nabulsi NB; Huang Y; Carson RE; van Dyck CH; Mecca AP
    bioRxiv; 2024 Sep; ():. PubMed ID: 39386453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging of mGluR5 in Alzheimer's disease.
    Mecca AP; McDonald JW; Michalak HR; Godek TA; Harris JE; Pugh EA; Kemp EC; Chen MK; Salardini A; Nabulsi NB; Lim K; Huang Y; Carson RE; Strittmatter SM; van Dyck CH
    Alzheimers Res Ther; 2020 Jan; 12(1):15. PubMed ID: 31954399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of [
    Chen MK; Mecca AP; Naganawa M; Gallezot JD; Toyonaga T; Mondal J; Finnema SJ; Lin SF; O'Dell RS; McDonald JW; Michalak HR; Vander Wyk B; Nabulsi NB; Huang Y; Arnsten AF; van Dyck CH; Carson RE
    J Cereb Blood Flow Metab; 2021 Sep; 41(9):2395-2409. PubMed ID: 33757318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of synthetic PET images of synaptic density and amyloid from
    Wang R; Liu H; Toyonaga T; Shi L; Wu J; Onofrey JA; Tsai YJ; Naganawa M; Ma T; Liu Y; Chen MK; Mecca AP; O'Dell RS; van Dyck CH; Carson RE; Liu C
    Med Phys; 2021 Sep; 48(9):5115-5129. PubMed ID: 34224153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment.
    Wang J; Huang Q; He K; Li J; Guo T; Yang Y; Lin Z; Li S; Vanderlinden G; Huang Y; Van Laere K; Guan Y; Guo Q; Ni R; Li B; Xie F
    Alzheimers Dement; 2024 Jun; 20(6):3876-3888. PubMed ID: 38634334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [
    O'Dell RS; Mecca AP; Chen MK; Naganawa M; Toyonaga T; Lu Y; Godek TA; Harris JE; Bartlett HH; Banks ER; Kominek VL; Zhao W; Nabulsi NB; Ropchan J; Ye Y; Vander Wyk BC; Huang Y; Arnsten AFT; Carson RE; van Dyck CH
    Alzheimers Res Ther; 2021 Jan; 13(1):11. PubMed ID: 33402201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
    Kumar A; Scarpa M; Nordberg A
    Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
    Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
    Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Mecca AP; Chen MK; O'Dell RS; Naganawa M; Toyonaga T; Godek TA; Harris JE; Bartlett HH; Zhao W; Nabulsi NB; Wyk BCV; Varma P; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    Alzheimers Dement; 2020 Jul; 16(7):974-982. PubMed ID: 32400950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [
    Mecca AP; Rogers K; Jacobs Z; McDonald JW; Michalak HR; DellaGioia N; Zhao W; Hillmer AT; Nabulsi N; Lim K; Ropchan J; Huang Y; Matuskey D; Esterlis I; Carson RE; van Dyck CH
    Neuroimage; 2021 Sep; 238():118217. PubMed ID: 34052464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer's disease: A [
    Wang J; He Y; Chen X; Huang L; Li J; You Z; Huang Q; Ren S; He K; Schibli R; Mu L; Guan Y; Guo Q; Zhao J; Xie F
    Alzheimers Res Ther; 2024 Jan; 16(1):9. PubMed ID: 38217040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET.
    Silva-Rudberg JA; Salardini E; O'Dell RS; Chen MK; Ra J; Georgelos JK; Morehouse MR; Melino KP; Varma P; Toyonaga T; Nabulsi NB; Huang Y; Carson RE; van Dyck CH; Mecca AP
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):17-28. PubMed ID: 37673749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principal component analysis of synaptic density measured with [
    O'Dell RS; Higgins-Chen A; Gupta D; Chen MK; Naganawa M; Toyonaga T; Lu Y; Ni G; Chupak A; Zhao W; Salardini E; Nabulsi NB; Huang Y; Arnsten AFT; Carson RE; van Dyck CH; Mecca AP
    Neuroimage Clin; 2023; 39():103457. PubMed ID: 37422964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of Metabotropic Glutamate Receptor 5 Availability With Both [
    Glorie D; Verhaeghe J; Miranda A; De Lombaerde S; Stroobants S; Staelens S
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2022 Jun; 7(6):607-615. PubMed ID: 34856382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo imaging of synaptic density with [
    Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
    Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo tau pathology is associated with synaptic loss and altered synaptic function.
    Coomans EM; Schoonhoven DN; Tuncel H; Verfaillie SCJ; Wolters EE; Boellaard R; Ossenkoppele R; den Braber A; Scheper W; Schober P; Sweeney SP; Ryan JM; Schuit RC; Windhorst AD; Barkhof F; Scheltens P; Golla SSV; Hillebrand A; Gouw AA; van Berckel BNM
    Alzheimers Res Ther; 2021 Feb; 13(1):35. PubMed ID: 33546722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [
    Finnema SJ; Toyonaga T; Detyniecki K; Chen MK; Dias M; Wang Q; Lin SF; Naganawa M; Gallezot JD; Lu Y; Nabulsi NB; Huang Y; Spencer DD; Carson RE
    Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synaptic density patterns in early Alzheimer's disease assessed by independent component analysis.
    Fang XT; Raval NR; O'Dell RS; Naganawa M; Mecca AP; Chen MK; van Dyck CH; Carson RE
    Brain Commun; 2024; 6(2):fcae107. PubMed ID: 38601916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study.
    Holland N; Malpetti M; Rittman T; Mak EE; Passamonti L; Kaalund SS; Hezemans FH; Jones PS; Savulich G; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2022 Mar; 145(1):340-348. PubMed ID: 34398211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.